Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4630

Sort by

Sort Order Select

Journal Articles

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Blood (2021) 138 (4): 331–343.

https://doi.org/10.1182/blood.2020010438

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

What can Heraclitus tell us about AML?

Arnold Ganser

Blood (2021) 137 (20): 2719–2720.

https://doi.org/10.1182/blood.2021011264

Published: 2021

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

Zemin Ren, Marcel Spaargaren, Steven T. Pals

Blood (2021) 137 (13): 1713–1718.

https://doi.org/10.1182/blood.2020008188

Published: 2021

Journal Articles

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Blood (2021) 137 (9): 1192–1195.

https://doi.org/10.1182/blood.2020008346

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Andrea J. Darzi, Samer G. Karam, Rana Charide, Itziar Etxeandia-Ikobaltzeta, Mary Cushman, Michael K. Gould, Lawrence Mbuagbaw, Frederick A. Spencer, Alex C. Spyropoulos, Michael B. Streiff, Scott Woller, Neil A. Zakai, Federico Germini, Marta Rigoni, Arnav Agarwal, Rami Z. Morsi, Alfonso Iorio, Elie A. Akl, Holger J. Schünemann

Blood (2020) 135 (20): 1788–1810.

https://doi.org/10.1182/blood.2019003603

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Blood (2020) 135 (18): 1517–1530.

https://doi.org/10.1182/blood.2019003633

Published: 2020

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Martin Stanulla, Hélène Cavé, Anthony V. Moorman

Blood (2020) 135 (4): 252–260.

https://doi.org/10.1182/blood.2019000813

Published: 2020

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Blood (2019) 134 (21): 1796–1801.

https://doi.org/10.1182/blood.2019001321

Published: 2019

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group

Blood (2019) 134 (Supplement_1): 652.

https://doi.org/10.1182/blood-2019-123236

Published: 2019

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Blood (2019) 134 (Supplement_1): 506.

https://doi.org/10.1182/blood-2019-123974

Published: 2019

Journal Articles

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Adam Zayac, MD, Andrew Matthew Evens, DO,MMSc, Andrzej Stadnik, MPH, BS, Stephen D. Smith, MD, Deepa Jagadeesh, MDMPH, Lori A. Leslie, MD, Catherine Wei, MD MA, Seo-Hyun Kim, MD, Seema Naik, MD, Suchitra Sundaram, MD, Nishitha Reddy, MD, Umar Farooq, MD, Vaishalee P. Kenkre, MD, Narendranath Epperla, MDMS, Kristie A. Blum, MD, Nadia Khan, MD, Daulath Singh, MD, Juan Pablo Alderuccio, MD, Amandeep Godara, MD, Maryam Yazdy, MD, Catherine Diefenbach, MD, Emma Rabinovich, MD, Gaurav Varma, MDMPH, Reem Karmali, MD, Yusra Shao, MD, Asaad Trabolsi, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Sarah Stettner, Ayushi Chauhan, MBBS, Yun Kyong Choi, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Michael C. Churnetski, Kirsten M Boughan, DO, Stephanie Berg, DO, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Christopher D'Angelo, MD, David A. Bond, MD, Seth M Maliske, MD, Ryan Vaca, MD, Gabriela Magarelli, APN, Amy Sperling, BS, Max J. Gordon, MD, Kevin A. David, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Parameswaran Venugopal, MD, Izidore S. Lossos, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 402.

https://doi.org/10.1182/blood-2019-122990

Published: 2019

Journal Articles

Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL

Carmina Louise Hugo Guerrero, MS, Yoshiko Yamashita, PhD, Megumi Kuba-Miyara, PhD, Naoki Imaizumi, PhD, Shugo Sakihama, PhD, Masaki Hayashi, MD, Takashi Miyagi, MD PhD, Satoko Morishima, MD PhD, Kennosuke Karube, MD PhD, Yuetsu Tanaka, PhD, Hiroaki Masuzaki, MD PhD, Takuya Fukushima, MD PhD

Blood (2019) 134 (Supplement_1): 660.

https://doi.org/10.1182/blood-2019-129817

Published: 2019

Journal Articles

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Shih-Shih Chen, PhD, Constantine S. Tam, MBBS (Hons), MD, Alan G. Ramsay, BSc,MSc,PhD, Priyadarshini Ravichandran, Natalia C. Couto-Francisco, Michael Ibrahim, Gerardo Ferrer, PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, He Zhou, Jacqueline C Barrientos, MD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2019) 134 (Supplement_1): 477.

https://doi.org/10.1182/blood-2019-127255

Published: 2019

Journal Articles

Incidence, Natural History and Outcomes of Transient and Persistent Antiphospholipid Antibodies in Children and Young Adults with Provoked Venous Thromboembolism: Analysis of the Kids-DOTT Trial

Marisol Betensky, MDMPH, Anh Thy Nguyen, MSPH, Cristina Tarango, MD, Anupam R Verma, MD, Rukhmi Bhat, MDMS, Nicole Kucine, MD, Charles Nakar, MD, Gary Woods, MD, Frances L Hamblin, MSHS, RN, Ernest Amankwah, PhD, Neil A Goldenberg, MD PhD

Blood (2019) 134 (Supplement_1): 636.

https://doi.org/10.1182/blood-2019-131438

Published: 2019

NARROW

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

What can Heraclitus tell us about AML?

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Erdheim-Chester disease

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Incidence, Natural History and Outcomes of Transient and Persistent Antiphospholipid Antibodies in Children and Young Adults with Provoked Venous Thromboembolism: Analysis of the Kids-DOTT Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only